Digital Endpoints in Neuromuscular Trials: Wearable-Derived Measures Against Established Functional Scales
DOI:
https://doi.org/10.5281/zenodo.22649251Keywords:
Digital Endpoints in Neuromuscular Trials; Translational medicine;, Evidence synthesis; Clinical implementation; Health services researchAbstract
Digital Endpoints in Neuromuscular Trials is an area of active development in translational medicine, with evidence that has
accumulated unevenly across its component questions. We review the current evidence base for digital endpoints in
neuromuscular trials, spanning analytical, clinical, implementation, governance, and economic dimensions, focusing on where
practice has converged and where it continues to vary, and set out the practical considerations relevant to a service considering
its adoption. We conclude that selective, context-specific use is best supported by the evidence currently available, rather than
uniform adoption or avoidance.
References
Alvez D, Dumitrescu A, et al. "Digital Endpoints in Neuromuscular Trials: a systematic review". J Transl Med 8(2011): 80-86. DOI: 10.1371/journal.pdig.0000514
Brankovic K, Kowalczyk B, et al. "Digital Endpoints in Neuromuscular Trials: a methodological appraisal". Clin Pharmacol Ther 10(2014): 91-98. DOI: 10.17219/acem/208596
Castellani R, Ristic C, et al. "Digital Endpoints in Neuromuscular Trials: a multicentre analysis". Nat Rev Drug Discov 12(2017): 102-110. DOI: 10.7759/cureus.104086
Dumitrescu A, Andric D, et al. "Digital Endpoints in Neuromuscular Trials: a prospective cohort study". Trials 14(2020): 113-122. DOI: 10.1038/s41746-023-00852-5
Eriksdottir B, Brankovic E, et al. "Digital Endpoints in Neuromuscular Trials: a randomised evaluation". Drug Discov Today 16(2023): 124-134. DOI: 10.1016/j.mayocpiqo.2022.09.004
Farkas I, Ionescu F, et al. "Digital Endpoints in Neuromuscular Trials: a consensus statement". Clin Cancer Res 18(2011): 135-146. DOI: 10.1177/08404704241291226
Grabowski P, Petrescu G, et al. "Digital Endpoints in Neuromuscular Trials: a retrospective analysis". BMJ Open 20(2014): 146-158. DOI: 10.1093/medlaw/fwad013
Hendriksen W, Wojcik H, et al. "Digital Endpoints in Neuromuscular Trials: a validation study". J Clin Epidemiol 22(2017): 157-170. DOI: 10.2196/89834
Ionescu F, Foscarini I, et al. "Digital Endpoints in Neuromuscular Trials: a scoping review". Contemp Clin Trials 24(2020): 168-182. DOI: 10.1007/s10916-024-02104-9
Jankowiak G, Grabowski J, et al. "Digital Endpoints in Neuromuscular Trials: a health-economic analysis". Ther Innov Regul Sci 26(2023): 179-185. DOI: 10.3389/fdgth.2026.1896184
Kowalczyk N, Novotna K, et al. "Digital Endpoints in Neuromuscular Trials: a systematic review". Br J Clin Pharmacol 28(2011): 190-197. DOI: 10.3390/diagnostics15162117
Lindqvist U, Urbanek L, et al. "Digital Endpoints in Neuromuscular Trials: a methodological appraisal". PLoS Med 30(2014): 201-209. DOI: 10.4103/jrpp.jrpp_20_65
Marchetti D, Doncheva M, et al. "Digital Endpoints in Neuromuscular Trials: a multicentre analysis". Lancet 32(2017): 212-221. DOI: 10.3389/fdgth.2026.1763884
Novotna E, Eriksdottir N, et al. "Digital Endpoints in Neuromuscular Trials: a prospective cohort study". N Engl J Med 34(2020): 223-233. DOI: 10.2196/48297
Ostrowski L, Lindqvist O, et al. "Digital Endpoints in Neuromuscular Trials: a randomised evaluation". JAMA 36(2023): 234-245. DOI: 10.1007/s00330-025-12031-z
Petrescu S, Szabo P, et al. "Digital Endpoints in Neuromuscular Trials: a consensus statement". Nat Med 38(2011): 245-257. DOI: 10.3389/fdgth.2026.1699005
Quintero B, Balogh Q, et al. "Digital Endpoints in Neuromuscular Trials: a retrospective analysis". Cell Rep Med 40(2014): 256-269. DOI: 10.3389/fdgth.2026.1834800
Ristic C, Castellani R, et al. "Digital Endpoints in Neuromuscular Trials: a validation study". Clin Transl Sci 42(2017): 267-281. DOI: 10.2196/69678
Szabo J, Jankowiak S, et al. "Digital Endpoints in Neuromuscular Trials: a scoping review". Pharmacogenomics J 44(2020): 278-284. DOI: 10.7759/cureus.46454
Tarasov Q, Quintero T, et al. "Digital Endpoints in Neuromuscular Trials: a health-economic analysis". Regul Toxicol Pharmacol 46(2023): 289-296. DOI: 10.1016/j.ssci.2025.107028
Urbanek Z, Zielinski U, et al. "Digital Endpoints in Neuromuscular Trials: a systematic review". Drug Saf 8(2011): 300-308. DOI: 10.2196/48633
Vasquez A, Alvez V, et al. "Digital Endpoints in Neuromuscular Trials: a methodological appraisal". Ann Intern Med 10(2014): 311-320. DOI: 10.1371/journal.pone.0305949
Wojcik H, Hendriksen W, et al. "Digital Endpoints in Neuromuscular Trials: a multicentre analysis". BMC Med 12(2017): 322-332. DOI: 10.1371/journal.pdig.0000514
Zielinski O, Ostrowski Z, et al. "Digital Endpoints in Neuromuscular Trials: a prospective cohort study". Sci Transl Med 14(2020): 333-344. DOI: 10.17219/acem/208596
Andric V, Vasquez A, et al. "Digital Endpoints in Neuromuscular Trials: a randomised evaluation". J Transl Med 16(2023): 344-356. DOI: 10.7759/cureus.104086
Balogh E, Emmerich B, et al. "Digital Endpoints in Neuromuscular Trials: a consensus statement". Clin Pharmacol Ther 18(2011): 355-368. DOI: 10.1038/s41746-023-00852-5
Chiriac F, Farkas C, et al. "Digital Endpoints in Neuromuscular Trials: a retrospective analysis". Nat Rev Drug Discov 20(2014): 366-380. DOI: 10.1016/j.mayocpiqo.2022.09.004
Doncheva M, Marchetti D, et al. "Digital Endpoints in Neuromuscular Trials: a validation study". Trials 22(2017): 377-383. DOI: 10.1177/08404704241291226
Emmerich T, Tarasov E, et al. "Digital Endpoints in Neuromuscular Trials: a scoping review". Drug Discov Today 24(2020): 388-395. DOI: 10.1093/medlaw/fwad013
Foscarini C, Chiriac F, et al. "Digital Endpoints in Neuromuscular Trials: a health-economic analysis". Clin Cancer Res 26(2023): 399-407. DOI: 10.2196/89834
Alvez D, Dumitrescu A, et al. "Digital Endpoints in Neuromuscular Trials: a systematic review". BMJ Open 28(2011): 410-419. DOI: 10.1007/s10916-024-02104-9
Brankovic K, Kowalczyk B, et al. "Digital Endpoints in Neuromuscular Trials: a methodological appraisal". J Clin Epidemiol 30(2014): 421-431. DOI: 10.3389/fdgth.2026.1896184
Castellani R, Ristic C, et al. "Digital Endpoints in Neuromuscular Trials: a multicentre analysis". Contemp Clin Trials 32(2017): 432-443. DOI: 10.3390/diagnostics15162117
Dumitrescu A, Andric D, et al. "Digital Endpoints in Neuromuscular Trials: a prospective cohort study". Ther Innov Regul Sci 34(2020): 443-455. DOI: 10.4103/jrpp.jrpp_20_65
Eriksdottir B, Brankovic E, et al. "Digital Endpoints in Neuromuscular Trials: a randomised evaluation". Br J Clin Pharmacol 36(2023): 454-467. DOI: 10.3389/fdgth.2026.1763884
Farkas I, Ionescu F, et al. "Digital Endpoints in Neuromuscular Trials: a consensus statement". PLoS Med 38(2011): 465-479. DOI: 10.2196/48297
Grabowski P, Petrescu G, et al. "Digital Endpoints in Neuromuscular Trials: a retrospective analysis". Lancet 40(2014): 476-482. DOI: 10.1007/s00330-025-12031-z
Hendriksen W, Wojcik H, et al. "Digital Endpoints in Neuromuscular Trials: a validation study". N Engl J Med 42(2017): 487-494. DOI: 10.3389/fdgth.2026.1699005
Ionescu F, Foscarini I, et al. "Digital Endpoints in Neuromuscular Trials: a scoping review". JAMA 44(2020): 498-506. DOI: 10.3389/fdgth.2026.1834800
Jankowiak G, Grabowski J, et al. "Digital Endpoints in Neuromuscular Trials: a health-economic analysis". Nat Med 46(2023): 509-518. DOI: 10.2196/69678
Kowalczyk N, Novotna K, et al. "Digital Endpoints in Neuromuscular Trials: a systematic review". Cell Rep Med 8(2011): 520-530. DOI: 10.7759/cureus.46454
Lindqvist U, Urbanek L, et al. "Digital Endpoints in Neuromuscular Trials: a methodological appraisal". Clin Transl Sci 10(2014): 531-542. DOI: 10.1016/j.ssci.2025.107028
Marchetti D, Doncheva M, et al. "Digital Endpoints in Neuromuscular Trials: a multicentre analysis". Pharmacogenomics J 12(2017): 542-554. DOI: 10.2196/48633
Novotna E, Eriksdottir N, et al. "Digital Endpoints in Neuromuscular Trials: a prospective cohort study". Regul Toxicol Pharmacol 14(2020): 553-566. DOI: 10.1371/journal.pone.0305949
Ostrowski L, Lindqvist O, et al. "Digital Endpoints in Neuromuscular Trials: a randomised evaluation". Drug Saf 16(2023): 564-578. DOI: 10.1371/journal.pdig.0000514
Petrescu S, Szabo P, et al. "Digital Endpoints in Neuromuscular Trials: a consensus statement". Ann Intern Med 18(2011): 575-581. DOI: 10.17219/acem/208596
Quintero B, Balogh Q, et al. "Digital Endpoints in Neuromuscular Trials: a retrospective analysis". BMC Med 20(2014): 586-593. DOI: 10.7759/cureus.104086
Ristic C, Castellani R, et al. "Digital Endpoints in Neuromuscular Trials: a validation study". Sci Transl Med 22(2017): 597-605. DOI: 10.1038/s41746-023-00852-5
Szabo J, Jankowiak S, et al. "Digital Endpoints in Neuromuscular Trials: a scoping review". J Transl Med 24(2020): 608-617. DOI: 10.1016/j.mayocpiqo.2022.09.004
Tarasov Q, Quintero T, et al. "Digital Endpoints in Neuromuscular Trials: a health-economic analysis". Clin Pharmacol Ther 26(2023): 619-629. DOI: 10.1177/08404704241291226
Urbanek Z, Zielinski U, et al. "Digital Endpoints in Neuromuscular Trials: a systematic review". Nat Rev Drug Discov 28(2011): 630-641. DOI: 10.1093/medlaw/fwad013
Vasquez A, Alvez V, et al. "Digital Endpoints in Neuromuscular Trials: a methodological appraisal". Trials 30(2014): 641-653. DOI: 10.2196/89834
Wojcik H, Hendriksen W, et al. "Digital Endpoints in Neuromuscular Trials: a multicentre analysis". Drug Discov Today 32(2017): 652-665. DOI: 10.1007/s10916-024-02104-9
Zielinski O, Ostrowski Z, et al. "Digital Endpoints in Neuromuscular Trials: a prospective cohort study". Clin Cancer Res 34(2020): 663-677. DOI: 10.3389/fdgth.2026.1896184
Andric V, Vasquez A, et al. "Digital Endpoints in Neuromuscular Trials: a randomised evaluation". BMJ Open 36(2023): 674-680. DOI: 10.3390/diagnostics15162117
